UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000041649 |
|---|---|
| Receipt number | R000047536 |
| Scientific Title | Assessment of inhibitory effect of letrozole on hepatic fibrosis |
| Date of disclosure of the study information | 2020/09/02 |
| Last modified on | 2025/03/31 11:00:36 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Assessment of inhibitory effect of letrozole on hepatic fibrosis
Acronym
Assessment of inhibitory effect of letrozole on hepatic fibrosis
Scientific Title
Assessment of inhibitory effect of letrozole on hepatic fibrosis
Scientific Title:Acronym
Assessment of inhibitory effect of letrozole on hepatic fibrosis
Region
| Japan |
Condition
Condition
The patients who were treated with letrozole and conducted blood tests of hepatic function
Classification by specialty
| Hepato-biliary-pancreatic medicine |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To assess the inhibitory effect on hepatic fibrosis by comparimg between the hepatic function parameters before and after letrozole administration
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Age, sex, platelet count, AST, ALT, BMI level (weight, height), blood glucose level, HbA1c, blood albumin
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Female
Key inclusion criteria
Not applicable
Key exclusion criteria
Not applicable
Target sample size
400
Research contact person
Name of lead principal investigator
| 1st name | Kazuyoshi |
| Middle name | |
| Last name | Okawa |
Organization
Osaka International Cancer Institute
Division name
Department of Hepatobiliary and Pancreatic Oncology
Zip code
541-8567
Address
3-1-69 Otemae, Chuo-ku, Osaka, Osaka
TEL
06-6945-1181
ohkawa-ka@mc.pref.osaka.jp
Public contact
Name of contact person
| 1st name | Kazuyoshi |
| Middle name | |
| Last name | Okawa |
Organization
Osaka International Cancer Institute
Division name
Department of Hepatobiliary and Pancreatic Oncology
Zip code
541-8567
Address
3-1-69 Otemae, Chuo-ku, Osaka, Osaka
TEL
06-6945-1181
Homepage URL
ohkawa-ka@mc.pref.osaka.jp
Sponsor or person
Institute
Osaka International Cancer Institute
Institute
Department
Personal name
Funding Source
Organization
Towa Pharmaceutical Co., Ltd
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Osaka International Cancer Institute
Address
Towa Pharmaceutical Co., Ltd
Tel
06-6945-1181
rinri01@opho.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2020 | Year | 09 | Month | 02 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2020 | Year | 07 | Month | 17 | Day |
Date of IRB
| 2020 | Year | 08 | Month | 04 | Day |
Anticipated trial start date
| 2020 | Year | 08 | Month | 27 | Day |
Last follow-up date
| 2022 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Not applicable
Management information
Registered date
| 2020 | Year | 09 | Month | 02 | Day |
Last modified on
| 2025 | Year | 03 | Month | 31 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047536
